ImmunologyOphthalmologyNeurologyHealth DiagnosticsDiabetesHematologyInfectious DiseasesRespiratoryDermatologyOncologyBiotechnologyHealth CareScience and Engineering
Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses.
Business Segments
The company operates through two primary business segments: Pharmaceuticals and Diagnostics.
Pharmaceuticals
This segment is the cornerstone of the comp…
Analysis
Quality compounder
Roche Holding AG earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is fair. The owner-earnings multiple stands at 21.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 10%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 16/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202324
29
2023202420252026
All-time high
30
May 2024
All-time low
6
Dec 2025
Average rank
17
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
55
31
39
36
Price/Earnings
47
56
70
58
Price/Book
22
10
12
10
Dividend Yield
81
74
94
92
Value (overall)
69
36
59
55
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.